Patent US5024938A successfully refreshed from Google Patents.
US5024938A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Recombinant DNA inserted with hepatitis B virus gene, mammalian cells transformed with cloned viral DNA, and production of hepatitis B virus proteins
Assignee: JURIDICAL FOUNDATIN CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
•
Filing: 1986-07-08
•
Granted: 1991-06-18
•
Expires: 2006-07-08
Abstract
Abstract A recombinant DNA comprising 3 fragments of Hepatitis B virus DNA recombined with a vector consisting essentially of 0.31 Kb replication orgin of SV40 DNA inserted into EcoRI cleavage site of Escherichia coli plasmid which is deficient in the 1.426-2.521 Kb region of inhibiting replication in mammalian cells, wherein each HBV DNA fragment is a 3.2 Kb BamHI fragment consisting of 1.9 Kb HBc gene and 1.3 Kb HBs gene, and said HBV DNA fragments are arranged in a head-to-tail tandem relationship wherein the HBc gene positions at the head and the HBs gene positions at the tail, mammalian cells transformed with the recombinant DNA, and a method of production of Hepatitis B virus proteins, i.e. HBsAg and/or HBeAg. These HBV proteins have the same immunological properties as those of the natural HBV proteins originated from human blood plasma and can be used for the preparation of HBV vaccine and diagnostic reagents.
Inventors
- 👤 Chikateru Nozaki
- 👤 Atsushi Miyanohara
- 👤 Fukusaburo Hamada
- 👤 Nobuya Ohtomo
- 👤 Kenichi Matsubara
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 14:06
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; C12; C12N; C12N2730/00; C12N2730/00011; C12N2730/10011; C12N2730/10111; C12N2730/10122
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
139 words
A recombinant DNA capable of replication in mammalian cells, which comprises 3 fragments of Hepatitis B virus subtype adr (HBV) DNA recombined with a vector, said vector comprising essentially of 0.31 Kb replication origin SV40 DNA inserted into the EcoRI cleavage site of Escherichia coli plasmid pBR322, wherein said plasmid is deficient in the 1.426-2.521 Kb region of inhibiting replication in mammalian cells and has an antibiotic resistant gene as a selective marker, wherein each of said HBV DNA fragments is comprised of a 3.2 Kb DNA having the BamHI site at both terminal ends, said BamHI DNA consisting of a 1.9 Kb HBc gene and a 1.3 Kb HBs gene, wherein said HBV DNA fragments are arranged in a head-to-tail tandem relationship wherein the HBc gene positions at the head and the HBs gene positions at the tail.
Claim 2
Dependent Claim
139 words
A recombinant DNA capable of replication in mammalian cells, which comprises 3 fragments of Hepatitis B virus subtype adr (HBV) DNA recombined with a vector, said vector comprising essentially of 0.31 Kb replication origin SV40 DNA inserted into the EcoRI cleavage site of Escherichia coli plasmid pBR322, wherein said plasmid is deficient in the 1.426-2.521 Kb region of inhibiting replication in mammalian cells and has an antibiotic resistant gene as a selective marker, wherein each of said HBV DNA fragments is comprised of a 3.2 Kb DNA having the BamHI site at both terminal ends, said BamHI DNA consisting of a 1.9 Kb HBc gene and a 1.3 Kb HBs gene, wherein said HBV DNA fragments are arranged in a head-to-tail tandem relationship wherein the HBc gene positions at the head and the HBs gene positions at the tail.
Claim 3
Dependent Claim
10 words
Recombinant DNA according to claim 1, having thymidine kinase DNA.
Claim 4
Dependent Claim
146 words
A mammalian cell transformed by recombinant DNA capable of replication in mammalian cells, wherein said recombinant DNA comprising 3 fragments of Hepatitis B virus subtype adr (HBV) DNA recombined with a vector said vector consisting essentially of 0.31 Kb replication origin SV40 DNA inserted into the EcoRI cleavage site of Escherichia coli plasmid pBR322, wherein said plasmid is deficient in the 1.426-2.521 Kb region of inhibiting replication in mammalian cells and has an antibiotic resistant gene as a selective marker, wherein each of said HBV DNA fragments is comprised of a 3.2 Kb DNA having the BamHI site at both terminal ends, said BamHI DNA consisting of a 1.9 Kb HBc gene and a 1.3 Kb HBs gene, wherein said HBV DNA fragments are arranged in a head-to-tail tandem relationship wherein the HBc gene positions at the head and the HBs gene positions at the tail.
Claim 5
Dependent Claim
146 words
A mammalian cell transformed by recombinant DNA capable of replication in mammalian cells, wherein said recombinant DNA comprising 3 fragments of Hepatitis B virus subtype adr (HBV) DNA recombined with a vector said vector consisting essentially of 0.31 Kb replication origin SV40 DNA inserted into the EcoRI cleavage site of Escherichia coli plasmid pBR322, wherein said plasmid is deficient in the 1.426-2.521 Kb region of inhibiting replication in mammalian cells and has an antibiotic resistant gene as a selective marker, wherein each of said HBV DNA fragments is comprised of a 3.2 Kb DNA having the BamHI site at both terminal ends, said BamHI DNA consisting of a 1.9 Kb HBc gene and a 1.3 Kb HBs gene, wherein said HBV DNA fragments are arranged in a head-to-tail tandem relationship wherein the HBc gene positions at the head and the HBs gene positions at the tail.
Claim 6
Dependent Claim
18 words
The transformed mammalian cell of claim 3 wherein said mammalian cell is a thymidine kinase deficient mammalian cell.
Claim 7
Dependent Claim
17 words
The transformed mammalian cell of claim 3, wherein the mammalian cell is a mouse LTK - cell.
Claim 8
Dependent Claim
16 words
The transformed mammalian cell according to claim 3, wherein said mammalian cell is a COS cell.
Claim 9
Dependent Claim
16 words
The transformed mammalian cell according to claim 3, wherein said recombinant DNA includes thymidine kinase DNA.
Claim 10
Independent Claim
176 words
A method for producing Hepatitis B virus subtype adr "e" antigen which comprises the steps of transforming a mammalian cell with recombinant DNA capable of replication in mammalian cells, wherein said recombinant DNA comprises 3 fragments of Hepatitis B virus subtype adr (HBV) DNA recombined with a vector said vector consisting essentially of 0.31 Kb replication origin SV40 DNA inserted into the EcoRI cleavage site of Escherichia coli plasmid pBR322, wherein said plasmid is deficient in the 1.426-2.521 Kb region of inhibiting replication in mammalian cells and has an antibiotic resistant gene as a selective marker, wherein each of said HBV virus DNA fragments is comprised of a 3.2 Kb DNA having the BamHI site at both terminal ends, said BamHI DNA consisting of a 1.9 Kb HBc gene and a 1.3 Kb HBs gene, wherein HBV DNA fragments are arranged in a head-to-tail tandem relationship wherein the HBc gene positions at the head and the HBs gene positions at the tail, incubating said transformed mammalian cells; and, collecting the produced Hepatitis B virus e antigen.
Claim 11
Independent Claim
176 words
A method for producing Hepatitis B virus subtype adr "e" antigen which comprises the steps of transforming a mammalian cell with recombinant DNA capable of replication in mammalian cells, wherein said recombinant DNA comprises 3 fragments of Hepatitis B virus subtype adr (HBV) DNA recombined with a vector said vector consisting essentially of 0.31 Kb replication origin SV40 DNA inserted into the EcoRI cleavage site of Escherichia coli plasmid pBR322, wherein said plasmid is deficient in the 1.426-2.521 Kb region of inhibiting replication in mammalian cells and has an antibiotic resistant gene as a selective marker, wherein each of said HBV virus DNA fragments is comprised of a 3.2 Kb DNA having the BamHI site at both terminal ends, said BamHI DNA consisting of a 1.9 Kb HBc gene and a 1.3 Kb HBs gene, wherein HBV DNA fragments are arranged in a head-to-tail tandem relationship wherein the HBc gene positions at the head and the HBs gene positions at the tail, incubating said transformed mammalian cells; and, collecting the produced Hepatitis B virus e antigen.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-06-17 | 1994-12-17 | 1995-06-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-06-17 | 1998-12-17 | 1999-06-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-06-17 | 2002-12-17 | 2003-06-18 | $7700.00 | Window Closed / Lapsed |